Oric Pharmaceuticals, Inc. ORIC Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $56.4M+23.5% | $45.67M-8.1% | $49.67M-34.5% | $75.86M+53.8% | $49.33M-17.0% | ||
| $225.54M-4.4% | $235.82M-0.7% | $237.47M+14.9% | $206.65M+33.8% | $154.39M-21.5% | ||
| $290.23M+0.6% | $288.47M-2.4% | $295.59M+1.5% | $291.12M+37.7% | $211.43M-19.4% | ||
| $2.15M-11.1% | $2.42M-5.6% | $2.56M-7.3% | $2.76M-8.6% | $3.02M+3.3% | ||
| $436.76M+6.8% | $408.89M-5.2% | $431.19M+24.3% | $346.86M+42.8% | $242.86M-11.4% | ||
| $2.9M-24.3% | $3.82M+31.9% | $2.9M-7.3% | $3.13M-39.3% | $5.16M+233% | ||
| $17.77M-13.0% | $20.42M+1.2% | $20.18M+11.8% | $18.05M+2.5% | $17.62M-29.1% | ||
| $21.21M-13.5% | $24.53M+1.1% | $24.27M+6.2% | $22.86M-1.1% | $23.12M-25.5% | ||
| $11K0.0% | $11K0.0% | $11K+22.2% | $9K+28.6% | $7K0.0% | ||
| -$728.01M-5.2% | -$692.24M-4.6% | -$661.74M-5.2% | -$629.15M-6.1% | -$592.8M-5.3% | ||
| $415.56M+8.1% | $384.36M-5.5% | $406.92M+25.6% | $324M+47.4% | $219.74M-9.6% | ||
| $436.76M+6.8% | $408.89M-5.2% | $431.19M+24.3% | $346.86M+42.8% | $242.86M-11.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Oric Pharmaceuticals, Inc.'s total assets?
- Oric Pharmaceuticals, Inc. (ORIC) holds $436.8M in total assets, up 79.8% year over year.
- How much debt does Oric Pharmaceuticals, Inc. have?
- Oric Pharmaceuticals, Inc. carries $3.3M in total debt against $415.6M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Oric Pharmaceuticals, Inc. have?
- Oric Pharmaceuticals, Inc. holds $56.4M in cash and equivalents.
- Can Oric Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 16.33 — current assets exceed current liabilities.
- Where does Oric Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Oric Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.